 | |||||
|
Stavudine Project leader: Merja Roivainen, PhD Description The large collaborative prospective cohort studies carried out in Finland suggest that common enterovirus infections typically associated with acute diseases are risk factors for chronic diseases, like type 1 diabetes T1D ; and myocardial infarction. In the case of T1D, enterovirus infections appear to be able to initiate or facilitate the pathogenetic processes progressively leading to type 1 diabetes, and sometimes also to precipitate overt clinical disease. We have been concentrating on mechanisms by which enteroviruses are capable of destroying insulin producing -cells, a phenomenon characteristic of the disease. Major achievements 1 ; In a collaborative study the first documented report of enterovirus infection in pancreatic islets of T1D patients. The finding suggests that during systemic EV infections, the virus may reach pancreatic islets and cause direct beta-cell damage. 2 ; Demonstration of a definite islet cell tropism of enterovirus infections in humans and an important species difference between men and mice in the cell type specificity of pancreatic enterovirus infection. In experimental infections in mice, the coxsackieviruses infect the exocrine tissue, in particular, while even in lethal cases the islets remain unaffected. 3 ; Demonstration of susceptibility of primary human insulin-producing beta-cells kept in culture to infections caused by several enterovirus serotypes, representing different genetic subgroups and known to act through a number of different receptor families. Thus, human islets in culture provide an excellent model for studies on pathogenesis of T1D, and to determine changes in islets that enteroviruses may cause. 4 ; Systematic characterization of prototype strains of EVs for beta-cell tropism revealed that consequences of virus replication on beta-cell survival and beta-cell specific function appear to be strongly serotype-dependent ranging from rapid cytolysis coinciding with the severe functional damage of the surviving cells to subtle morphological changes sometimes associated with enhanced insulin release after proper stimuli. However, analyses of field isolates revealed that all studied serotypes appear to include strains with the definite capability to damage beta cells. 5 ; Identification of cell surface proteins of human beta-cells recognized by the selected enteroviruses as their receptors. The receptor specificity of islet cell-replicating echoviruses remained to be undiscovered since no evidence was found for the cell surface expression of the decay-accelerating factor known to act as a receptor for several echoviruses in established cell lines. Key publications Roivainen M, Rasilainen S, Ylipaasto P, Nissinen R, Ustinov J, Bouwens L, Eizirik D, Hovi T, and Otonkoski T. Mechanisms of coxsackievirus induced damage to human pancreatic beta cells. J Clin Endocrinology and Metabolism 2002; 85: 1-9. Pharmacy owners, who do not have to be qualified pharmacists, are known legally as authorised sellers of poisons, for example, lamivudine stavudine. 1. Expression at plasma membrane and organelles MITOCHONDRIAL TOXICITY OF ANTIVIRAL NUCLEOSIDES ex: FIALURIDINE FIAU ; , AZT, STAVUDINE ; FIAU ENT1 FIAU FIAU 3P ; ENT1. ANTIRETROVIRALS NRTIs- abacavir Ziagen ; , abacavir lamivudine Epzicom ; , abacavir lamivudine zidovudine Trizivir ; , didanosine ddI, Videx ; , emtricitabine Emtriva ; , lamivudine Epivir, 3TC ; , lamivudine zidovudine Combivir ; , stavudine d4T, Zerit ; , tenofovir Viread ; , tenofovir emtricitabine Truvada ; , zalcitabine ddC, Hivid ; , zidovudine AZT, Retrovir ; . PIs- amprenavir Agenerase ; , atazanavir Reyataz ; , fosamprenavir Lexiva ; , indinavir Crixivan ; , lopinavir ritonavir Kaletra ; , nelfinavir Viracept ; , ritonavir Norvir ; , saquinavir Fortovase, Invirase ; . NNRTIsdelavirdine Rescriptor ; , efavirenz Sustiva ; , nevirapine Viramune ; . Entry Inhibitors- none. OI DRUGS PHS "A1 OI"s- acyclovir Zovirax ; , azithromycin Zithromax ; , fluconazole Diflucan ; , leucovorin Wellcovorin ; , pentamidine NebuPent, Pentam ; , TMP SMX Bactrim ; . Other OIs- clotrimazole Mycelex ; , dapsone, nystatin Mucostatin. Wednesday, February 27, 2002, Seattle, Washington In a plenary presentation noteworthy for a crystal-clear discussion of a very complex topic, John Mellors[1] of the University of Pittsburgh described the specific mechanisms of nucleoside reverse transcriptase inhibitor NRTI ; resistance, and explained the observed levels of resistance associated with the various patterns of mutations encountered in clinical practice. The mutations associated with resistance to zidovudine were identified by Brendan Larder and colleagues[2] over a decade ago, well before any other antiretroviral drug was approved. These mutations -- 41L, 67N, 70R, F, and 219E Q --tend to accumulate during continued exposure to zidovudine in the absence of good viral suppression. Recently, it has been appreciated that these mutations can also be selected by stavudine, and that they have implications for resistance to all drugs in the NRTI class and to the recently FDA-approved nucleotide reverse transcriptase inhibitor, tenofovir. Reverse transcription is the process whereby the single-stranded HIV RNA genome is converted to a double-stranded DNA version that can be integrated into the chromosome of the infected cell. The RNA genome serves as a template, and reverse transcriptase adds deoxynucleotide triphosphates dNTPs ; one at a time as the viral DNA chain elongates. During this process, 2 of the 3 phosphate groups are cleaved off; this double phosphate is called pyrophosphate. At the end of the chain, there is a hydroxy group OH ; , which allows the next nucleoside monophosphate to be added onto the end of the chain. All of the NRTIs are "chain terminators" because they have a substitution other than OH at the end, and thus do not allow addition of the next building block. The process of adding a new building block involves 3 steps: 1. 2. 3. Binding of the next nucleoside or nucleoside analogue NRTI ; triphosphate Incorporation onto the end of the growing viral DNA chain and release of pyrophosphate Translocation of the incorporated nucleoside to a different position to allow room for addition of the next nucleoside residue. Results: Vancomycin fell 69% after 12 h of HVHF. Urine output was 200ml during this period in both patients indicating that extracorporeal clearance contributed mainly to this reduction. Table: Results Patient 1 Plasma creatinine 0h mg dl ; BUN mg dl ; Urine output ml 24h ; Vancomycin level 0h ug ml ; Vancomycin level at 12h % of reduction 1.56 35 132 Patient 2 2.31 39 and zerit. PERIPHERAL NEUROPATHY. Suspend if peripheral neuropathy develops--characterized by persistent numbness, tingling or pain in feet or hands; if symptoms resolve satisfactorily on withdrawal, and if stavudine needs to be continued, resume treatment at half previous dose. 100 Argov Z, Mastaglia FL. Disorders of neuromuscular transmis sion caused by drugs. N Engi J Med 1979; 301: 409-13 Chang CC, Chion IC, Hwang LL, Huang CY. Mechanisms of the synergisticactions between organic calcium channel antag and ticlid, for example, pregnancy. Stavudine hydrochlorideGraylands Hospital Drug Bulletin 2006 Vol. 14 No. 2 July ISSN 1323-1251 and ticlopidine. Table 1. Summary of data and results for nucleoside, nucleotide and non-nucleoside reverse transcriptase inhibitors and fusion inhibitor. The intracellular half-life was used when it was known, since nucleoside intracellular half-lives differ greatly from the half-life in plasma. The decay rate dR was calculated according to the formula dRZ24 log 2 ; T1 2, where T1 2 is the half-life. The threshold levels for 10- and 50-fold resistance R 10 ; and R 50 ; , respectively ; were calculated using an antiviral effect limit of 1! 2 see figure 1 ; . The penultimate column shows the number of doses that may be missed before 50-fold resistance emerges, assuming that the drug is able to control the mutant strain with perfect adherence. The final column shows the number of successive doses that must be taken after missing these doses, to be within a 1% tolerance of perfect adherence. In all cases, the numbers of missable and subsequent doses were estimated conservatively; for example, the missable dose threshold for Emtricitabine was 16.49 doses, while the subsequent dose threshold was 10.79, so this translates to 16 missable doses and 11 subsequent doses. ; drug Abacavir ABC ; Didanosine ddI ; Emtricitabine FTC ; Lamivudine 3TC ; Stzvudine d4T ; Tenofivir TDF ; Zalcitabine ddC ; Zidovudine ZDV ; Delavirdine DLV ; Efavirenz EFV ; Nevirapine NVP ; Enfuvirtide T20 ; Ri mM ; 12 4.65 7.2 t days ; 1 2 1 eK8 eK5 eK8 eK5 eK6 eK5 eK8 eK12 eK7 eK8 eK10 eK9. Through 48 weeks of therapy, there was a statistically significantly higher proportion of patients in the KALETRA arm compared to the investigator-selected protease inhibitor s ; arm with HIV RNA 400 copies mL 57% vs. 33%, respectively ; . Through 48 weeks of therapy, the mean increase from baseline in CD4 cell count was 111 cells mm3 for the KALETRA arm and 112 cells mm3 for the investigator-selected protease inhibitor s ; arm. Other Studies Study 720: KALETRA BID + stavudine + lamivudine Study 765: KALETRA BID + nevirapine + NRTIs Study 720 patients without prior antiretroviral therapy ; and study 765 patients with prior protease inhibitor therapy ; are randomized, blinded, multi-center trials evaluating treatment with KALETRA at up to three dose levels 200 100 mg BID [720 only], 400 100 mg BID, and 400 200 mg BID ; . Patients in study 720 had a mean age of 35 years, 70% were Caucasian, and 96% were male, while patients in study 765 had a mean age of 40 years, 73% were Caucasian, and 90% were male. Mean range ; baseline CD4 cell counts for patients in study 720 and study 765 were 338 3-918 ; and 372 72-807 ; cells mm3, respectively. Mean range ; baseline plasma HIV-1 RNA levels for patients in study 720 and study 765 were 4.9 3.3 to 6.3 ; and 4.0 2.9 to 5.8 ; log10 copies mL, respectively. Through 72 weeks of treatment, for patients randomized to the 400 100 mg BID dose of KALETRA, the proportion of patients with plasma HIV-1 RNA 400 50 ; copies mL was 80% 78% ; in study 720 [n 51] and 75% 58% ; in study 765 [n 36]. The corresponding mean increase in CD4 cell count was 256 cells mm3 for study 720 and 174 cells mm3 for study 765. At 72 weeks, 13 patients 13% ; had discontinued study 720 for any reason, including four discontinuations 4% ; secondary to adverse events or laboratory abnormalities with one of these discontinuations 1% ; being attributed to a KALETRA adverse event. In study 765, 13 patients and tegaserod. Jun 18, 2007 aidsmap, in a separate analysis, current treatments associated with the greatest risk of diabetes were indinavir, lamivudine-stavudine, didanosine-stavudine, india' s strides arcolab receives fda approval for two hiv aids. Stavudine orderStavudine alcohol
Limit salt added to foods while cooking or at the table to one-fourth of a teaspoon each day.
Jg 1 05 can you tell me what the negative effects on the face skin are of using illegal drugs, cocaine and urso. It is in class of drugs called reverse transcriptase inhibitors which also includes zalcitabine hivid ; , zidovudine retrovir ; , didanosine videx ; , and atavudine zerit. CLINICAL EFFICACY Atazanavir in nave subjects Three studies compared unboosted atazanavir 400 mg QD to either nelfinavir BMS-007 and BMS-008 trials ; or efavirenz BMS-034 trial ; in treatment-nave patients. The BMS-007 trial Sanne et al., 2003 ; was a phase-2 dose-finding trial on 420 patients, which compared different doses of unboosted atazanavir to nelfinavir, each in combination with ztavudine and didanosine, showing similar virological and immunological efficacy over 48 weeks. In the BMS-008 trial Murphy et al., 2003 ; 467 patients were randomized to receive either atazanavir 400 mg or 600 mg or nelfinavir 1250 mg BID, with an NRTI backbone of stavudine and. Stranded RNA genome into a double-stranded DNA copy for integration into the host cell genome. Although almost all aspects of the HIV-1 life cycle have been targeted 13 ; , a majority of the drugs that have been effective in clinical trials are nucleoside reverse transcriptase inhibitors NRTIs ; . However, treatment with NRTIs is limited by their toxicity to the host often through their interaction with mitochondrial DNA polymerase 4 7 and the ability of the virus to mutate and gain resistance 8 ; . Other factors that affect the ability of these inhibitors to reduce viral replication are uptake, transport, metabolism, and incorporation of the drug. All clinically used nucleoside analogs lack 3 -hydroxyl groups and are metabolically activated by host cellular kinases to their triphosphate forms. Compounds currently approved by the Food and Drug Administration are -D- ; -3 -azido-3 -deoxythymidine AZT or zidovudine ; , -D- ; -2 , 3 -didehydro-3 -deoxythymidine D4T or stavudine ; , -L- ; -2 , 3 -dideoxy-3 -thiacytidine 3TC or lamivudine ; , -D- ; -2 , 3 -dideoxycytidine, -D- ; -2 , 3 dideoxyinosine, 1S, 4R ; -4-[2-amino-6- cyclopropyl-amino ; succinate abacavir or ziagen ; , and R ; -9- 2-phosphonylmethoxy-propyl ; adenine PMPA ; . HIV-1's high rate of replication and the lack of proofreading by RT during viral replication leads to frequent mutations 9 12 ; . Distinct mutations occur in the presence of different NRTIs, and their temporal occurrence is often predictable 13 18 ; . Initial mutations are often responsible for resistance to the compound, whereas later mutations increase the fitness of the mutant virus 19 ; . The mutations that are responsible for conferring nucleoside drug resistance are primarily clustered in three regions of the protein as illustrated in Fig. 1. These include the dNTP binding site region II ; , the site near the n 1 templating base region III ; , and the putative ATP binding site region I ; . These mutations have been shown to cause resistance by two distinct mechanisms. The first mechanism of resistance appears to be related to a change in the incorporation of the activated drug into the replicating viral genome. These mutations are often found to be in direct contact with the incoming dNTP in the active site of RT and impede nucleotide analog incorporation and thereby show altered reaction kinetics Fig. 1, region II ; 20 25, 42 ; . This has been best illustrated by steric hindrance interfering with 3TCTP binding in the active site of HIV-1 RT containing a Met184 to Val mutation 20, 26, 27 ; . Additionally, other mutations have also been noted that contact the n 1 templating base and appear to cause resistance at the level of incorpora. These drugs were initially used as recreational drugs at clubs and raves, but soon became used to incapacitate victims for the purpose of sexual assault and zerit. While studies show benefit in severity of neurological deficits caused by cerebral vasospasm following sah, no evidence shows that the drug either prevents or relieves spasm of cerebral arteries. Hoechst Marion Roussel notified the FDA on October 10, 1995 of the withdrawal of the cholesterol-lowering agent probucol Lorelco ; from the market. Probucol lowers LDL cholesterol levels; however, it also lowers HDL cholesterol levels, an unfavorable lipid effect. The FDA began considering the withdrawal of the drug about a year ago because of concerns over probucol's efficacy and not because of any specific adverse event reports. Probucol has been reported to cause prolongation of the QT interval and serious arrhythmias in patients receiving the drug alone or concomitantly with antiarrhythmic agents. Probucol was not included in the pharmacoeconomic analysis of hyperlipidemia because its role in the treatment of elevated cholesterol levels is not clear, particularly given its effects on HDL cholesterol! Medication Compliance Aids Selection Criteria "Best Practices for Improvement in Management of Oral Medications" OASIS ANSWERS, Inc. 2005. Stavudine cream
ABSTRACT The PhD study was carried out as a collaborative research project between the Department of Infectious Diseases, Skejby Hospital and Department of Nutritional and Metabolism, Massachusetts General Hospital, Boston. The dissertation consists of three publications and a summarizing review. The introduction of highly active retroviral therapy HAART ; has markedly improved the prognosis for HIV-infected patients. However, accumulating data suggest that HIV-infection and HAART can cause a syndrome of lipodystrophy associated with metabolic abnormalities contributing to increased mortality in HIV-patients. The main focus of this thesis was to further understand how HIVlipodystrophy affects reproductive indices and cardiovascular risk in HIV-infected women. This was assessed in a cohort of 200 HIV-infected women and matched controls. To separate the effect of HIV from that of HAART the effect of stavudine treatment for a month on mitochondrial number and activity in skeletal muscle of healthy adults were investigated as well as how mitochondrial changes influenced overall insulin sensitivity. This was done in a placebo-controlled prospective randomized study. Changes in body composition were seen in approximately twothirds of HIV-infected women and rates of impaired glucose tolerance and hyperinsulinemia were also significantly increased. The numbers of women identified with polycystic ovaries were identical in the two groups but levels of sex hormone binding globulin were significantly increased in the HIV-infected women. This may be one factor contributing to the absence of polycystic ovaries in hyperinsulinemic and centrally obese HIV-infected women. Carotid intimal media thickness IMT ; , a surrogate marker of atherosclerosis, was increased significantly in the protease-inhibitor treated HIV-infected women; however no correlation between HIV-infection and carotid IMT was found. In the randomized prospective study of the effect of stavudine in healthy adults, we found a reduction of mitochondrial DNA as well as a reduction in insulin sensitivity in the stavudine treated group compared to the placebo treated group. Additionally a correlation between insulin sensitivity and mitochondrial function was found suggesting a mechanism by which NRTI can induce insulin resistance in HIV-infected patients. These findings adds to the current knowledge of the occurrence of HIV-lipodystrophy and associated metabolic disturbances and how this may affect important risk factors for disease such as diabetes, heart disease, metabolic syndrome, and reproductive function. Fur176. © 2005-2007 Generic.fizwig.com, Inc. All rights reserved. |
||||